Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older; XEPI, (ozenoxacin) cream, a quinolone antimicrobial for the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult and pediatric patients 2 months of age and older; and XEGLYZE, a pediculicide indicated for topical treatment of head lice infestation in patients 6 months of age and older. It also provides NITRICIL, a proprietary nitric oxide-based technology platform. The company was formerly known as Channel Therapeutics Corporation and changed its name to Pelthos Therapeutics Inc. in July 2025. Pelthos Therapeutics Inc. was founded in 2002 and is based in Durham, North Carolina.
Frequently asked questions
What sector does PTHS (PTHS) operate in?
PTHS belongs to the Healthcare sector and operates in the Biotechnology industry.
What is PTHS (PTHS) current stock price?
As of the latest data, PTHS stock price is $15.20, with a previous close of $17.00. PTHS lost -$1.80 in the last trading session, representing a -10.59% loss.
What is PTHS (PTHS) current market capitalization?
PTHS market cap is approximately 58.19 million.
What is PTHS (PTHS) Earnings Per Share (EPS)?
The trailing EPS is -$28.63, and the forward EPS is -$5.68.
What is PTHS (PTHS) EBITDA?
PTHS EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -15.93 million.
Does PTHS (PTHS) pay dividends?
No. PTHS does not pay a dividend.
How did PTHS (PTHS) perform in its most recent earnings report?
In the last report (June 30, 2026), PTHS posted an EPS surprise of -119.21% and a revenue surprise of 2.55%.
What is PTHS (PTHS) beta (volatility) score?
PTHS has a beta of 3.047, indicating very high volatility compared to the market.
